Reasons to Invest

• First MGO honey-based wound dressing patented formulations with anticipated FDA microbial claim
• Our advanced wound care dressings will address the antimicrobial resistance (AMR) crisis
• Our bioactive buckwheat honey products promote faster and healthier healing

VIEW CAMPAIGN

The Problems

Anti-microbial Resistance (AMR) Crisis

* Anti-microbial infections currently kill 700,000+ people

* Globally projected to increase to 10 million people per year by 2050

Diabetic Foot Ulcers (DFU)

* Estimated 26 million patients develop DFUs globally

* Last 13 months and recur in up to 70% of patients

* Results in 15% requiring amputations with 47% ending in death


Radiation, Chemical and Thermal Burns
* Few effective therapies for radiotherapy, laser therapy and minor thermal burns

* Of the 3 million patients receiving radiation, 85% experience moderate to severe skin reactions

The Solutions

Anti-microbial Resistance (AMR) Crisis
* Our BEECure™ M patented formulation reduces microbial growth

* Our BEECure™ M provides a barrier to prevent life threatening bacteria (MRSA) from penetrating the dressing

Diabetic Foot Ulcers (DFU)

* Case studies illustrated superior clinical outcomes with accelerated healing and skin regeneration of severe limb threatening wounds

Radiation, Chemical and Thermal Burns

* Honey dressings make the wounds sterile in less time, enhance healing, and have a better outcome in terms of hypertrophic scars and postburn contractures, as compared to silver sulfadiazine dressings.